Recombinant Human IGF2BP2/IMP-2 protein
Recombinant Human IGF2BP2/IMP-2 protein
Be the first to review this product! Submit a review
|
(1 Publication)
Recombinant Human IGF2BP2/IMP-2 protein is a Human Fragment protein, in the 1 to 220 aa range, expressed in Escherichia coli, with >95%, < 1 EU/µg endotoxin level, suitable for SDS-PAGE, HPLC.
別名を表示する
IMP2, VICKZ2, IGF2BP2, Insulin-like growth factor 2 mRNA-binding protein 2, IGF2 mRNA-binding protein 2, IMP-2, Hepatocellular carcinoma autoantigen p62, IGF-II mRNA-binding protein 2, VICKZ family member 2
- SDS-PAGE
Supplier Data
SDS-PAGE - Recombinant Human IGF2BP2/IMP-2 protein (AB173053)
SDS-PAGE analysis of Recombinant Human IGF2BP2 (ab173053).
Lane 1 + 2 : Recombinant Human IGF2BP2.
Lane 3 : Molecular weight markers.
Reactivity data
製品の詳細
配列情報
出荷温度及び保存条件
製品の状態
出荷温度
短期保存温度
長期保存温度
保管に関する情報
一般的な情報
機能
RNA-binding factor that recruits target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation (By similarity). Preferentially binds to N6-methyladenosine (m6A)-containing mRNAs and increases their stability (PubMed : 29476152). Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs (PubMed : 9891060). Binding is isoform-specific. Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA stability by binding to the coding region instability determinant (CRD) and binding is enhanced by m6A-modification of the CRD (PubMed : 29476152).
配列の類似性
Belongs to the RRM IMP/VICKZ family.
ターゲットの情報
文献 (1)
Recent publications for all applications. Explore the full list and refine your search
Frontiers in oncology 11:680642 PubMed34386421
2021
Applications
Unspecified application
Species
Unspecified reactive species
Abcam product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com